Case-Based Roundtable Meetings Spotlight May 2021: Hematologic Malignancies

During a Targeted Oncology Case-Based Roundtable event, Sikander Ailawadhi, MD, discussed maintenance therapy for patients with multiple myeloma.

Various frontline treatments can be administered to a patient with newly-diagnosed multiple myeloma. Rafael Fonseca, MD, and a group of peers compare the available agents during a Targeted Oncology, Cased- Based Roundtable event.

David H. Vesole, MD, PhD, discussed triplet regimens used for the treatment of transplant ineligible multiple myeloma during a Targeted Oncology Case-Based Roundtable event.

David Dingli, MD, PhD, professor of Medicine at the Mayo Clinic, discussed the treatment options available for patients with transplant-eligible multiple myeloma with a group of peers during a Targeted Oncology Case-Based Roundtable event.

Based on clinical trial research, ruxolitinib is a viable option for the treatment of acute graft-versus-host-disease. The agent has been shown to induce durable responses.

Joseph Mikhael, MD, explained the prognostic factors for consideration when treating newly-diagnosed multiple myeloma.

Noa Biran, MD, moderated a Targeted Oncology Case-Based Roundtable event during which time experts discussed treatment rationale in multiple myeloma.

Seema A. Bhat, MD, discussed the case of 61-year-old patient with chronic lymphocytic leukemia during a Targeted Oncology Case-Based Roundtable event.

Zanetta Lamar, MD, discussed the efficacy of tafasitamab in combination with lenalidomide in the clinical trial setting.

The most recent data on ruxolitinib support its continued use as frontline treatment of patients with myelofibrosis.